Johnson & Johnson announced new patient data from the Phase 2 DAHLIAS study showing nipocalimab significantly improves mouth dryness, the most impactful symptom for Sjögren's disease patients. The drug also increased saliva production by 50% in more patients compared to placebo. These findings support ongoing Phase 3 trials evaluating nipocalimab's broader benefits on symptoms like fatigue, eye dryness, and joint pain. Nipocalimab is the only Fc receptor blocker with FDA Breakthrough Therapy and Fast Track designations for moderate-to-severe Sjögren's disease, highlighting its potential as a targeted treatment for this chronic autoimmune condition.
Johnson & Johnson shares are trading near their 52-week high of $278.43, currently priced at $276.22 on Pluang as of Nov 07, 2026 22:21 WIB, showing a 1.43% gain in one day. This price is significantly above the 52-week low of $186.57, reflecting strong investor interest despite a nearly balanced order activity with 53% selling and 47% buying. The stock's dividend yield stands at 1.94%, and the typical hold time on Pluang is 130 days, indicating moderate investor confidence in the health sector giant amid ongoing clinical developments.
Johnson & Johnson announced positive Phase 3 trial results for ICOTYDE (icotrokinra), an oral peptide targeting IL-23R, in treating biologic-naïve adults with active psoriatic arthritis. At 16 weeks, 58% of patients achieved ACR20 response versus 41%...
As of late 2026, the average 1-year certificate of deposit (CD) rate stands at 1.76%, below the Federal Reserve's target range. Some investors are considering blue-chip dividend stocks like Microsoft, Johnson & Johnson, and Coca-Cola, which offer pot...
The FDA granted accelerated approval to Johnson & Johnson's RYBREVANT FASPRO, a dual-targeted therapy for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have progressed after platinum-based chemotherapy and anti...
Five dividend-paying stocks in sectors like pharmaceuticals, software, food, and utilities are highlighted for their strong dividend coverage and resilience during economic slowdowns. Johnson & Johnson, IBM, Pfizer, General Mills, and Dominion Energy...
Johnson & Johnson announced the FDA's accelerated approval of RYBREVANT FASPRO, a dual-targeted subcutaneous therapy for adults with recurrent or metastatic head and neck squamous cell carcinoma after platinum-based chemotherapy and anti-PD-(L)1 anti...
